A. Tzouvelekis (Athens, Greece), J. Morisset (Montréal (QC), Canada)
A Telemonitoring Homecare Platform for patients with Pulmonary Fibrosis
F. Malli (Larissa, Greece), O. Kotsiou (Larissa, Greece), P. Tsanakas (Athens, Greece), I. Maglogiannis (Athens, Greece), K. Antoniou (Heraklion, Greece), D. Papakosta (Thessaloniki, Greece), E. Vasarmidi (Heraklion, Greece), C. Efthymiou (Thessaloniki, Greece), K. Gourgoulianis (Larissa, Greece), Z. Daniil (Larissa, Greece)
|  |
HOME MONITORING WITH A PORTABLE OXYMETER AS AN ALTERNATIVE METHOD TO ASSESS OXYGEN SATURATION DURING DAILY ACTIVITIES IN INTERSTITIAL LUNG DISEASES (ILDs).
S. Cuerpo (Barcelona, Spain), J. Francesqui (Barcelona, Spain), F. Hernandez (Barcelona, Spain), M. Palomo (Barcelona, Spain), C. Hernandez (Barcelona, Spain), I. Torralbo (Barcelona, Spain), C. Embid (Barcelona, Spain), I. Blanco (Barcelona, Spain), J. Sellares (Barcelona, Spain)
| |
IMPROVING HOME OXIGEN THERAPY IN PATIENTS WITH INTERSTITIAL LUNG DISEASES (ILDs): APPLICATION OF A PORTABLE NON-INVASIVE VENTILATION (NIV) DEVICE
S. Cuerpo (Barcelona, Spain), J. Francesqui (Barcelona, Spain), F. Hernandez (Barcelona, Spain), M. Palomo (Barcelona, Spain), C. Hernandez (Barcelona, Spain), I. Blanco (Barcelona, Spain), C. Embid (Barcelona, Spain), J. Sellares (Barcelona, Spain)
| |
Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy.
K. Kataoka (Seto, Japan), K. Oda (Kitakyusyu, Japan), H. Takizawa (Mitaka, Japan), T. Ogura (Yokohama, Japan), A. Miyamoto (Tokyo, Japan), M. Sekiguchi (Sakai, Japan), S. Akagawa (Kiyose, Japan), S. Hashimoto (Tenri, Japan), T. Kishaba (Uruma, Japan), Y. Hasegawa (Nagoya, Japan), N. Hamada (Fukuoka, Japan), K. Kuwano (Tokyo, Japan), M. Nakayama (Shimono, Japan), M. Ebina (Sendai, Japan), N. Enomoto (Hamamatsu, Japan), Y. Miyazaki (Tokyo, Japan), K. Atsumi (Tokyo, Japan), S. Izumi (Tokyo, Japan), Y. Tanino (Fukushima, Japan), H. Ishii (Fukuoka, Japan), H. Ohnishi (Nankoku, Japan), Y. Kondoh (Seto, Japan)
|  |
Risk factors for diagnostic delay in a prospective IPF-cohort
N. Hoyer (Hellerup, Denmark), T. Prior (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), T. Wilcke (Hellerup, Denmark), S. Shaker (Hellerup, Denmark)
| |
Differences of acute exacerbations in idiopathic pulmonary fibrosis compared to other fibrotic lung diseases
P. Faverio (Monza, Italy), S. Cerri (Modena, Italy), M. Pellegrino (Modena, Italy), G. Dei (Monza, Italy), E. Clini (Modena, Italy), F. Luppi (Monza, Italy), A. Pesci (Monza, Italy)
| |
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Z. Bingol (Istanbul, Turkey), S. Oguz (Istanbul, Turkey), Z. Kilicaslan (Istanbul, Turkey), E. Kiyan (Istanbul, Turkey), G. Okumus (Istanbul, Turkey)
| |
Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
I. Raats- ten Cate (Leeuwarden, Netherlands), C. Van Moorsel (Nieuwegein, Netherlands), A. Van Der Meer (Leeuwarden, Netherlands), P. Zanen (Nieuwegein, Netherlands), J. Grutters (Nieuwegein, Netherlands)
| |
Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.
C. Hayton (Manchester, United Kingdom), F. Elsawy (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), P. Rivera-Ortega (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
| |
Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
M. van Manen (Rotterdam, Netherlands), S. Birring (London, United Kingdom), C. Vancheri (Catania, Italy), A. Odink (Rotterdam, Netherlands), B. Hussain (Rotterdam, Netherlands), V. Vindigni (Catania, Italy), E. Renzoni (London, United Kingdom), A. Russell (London, United Kingdom), M. Wapenaar (Rotterdam, Netherlands), V. Cottin (Lyon, France), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI
F. Caro (Buenos Aires, Argentina), I. Buendia Roldán (Mexico, Mexico), P. Curbelo (Montevideo, Uruguay), R. Kairalla (Sao Pablo, Brazil), M. Mejía (Mexico, Mexico), L. Noriega (Panamá City, Panama), F. Paulin (Buenos Aires, Argentina), A. Undurraga (Santiago, Chile), M. Selman (Mexico, Mexico), O. Refipi Group (Montevideo, Uruguay)
| |
Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases
A. Llanos-González (Santa Cruz de Tenerife, Spain), J. Bordas Martínez (Barcelona, Spain), G. Bermudo Peloche (Barcelona, Spain), G. Suárez-Cuartín (Barcelona, Spain), V. Vicens Zygmunt (Barcelona, Spain), L. Planas-Cerezales (Barcelona, Spain), J. Palma López (Barcelona, Spain), L. Pérez Martín (Santa Cruz de Tenerife, Spain), R. Jodar Masanes (Barcelona, Spain), N. Padulles Zamora (Barcelona, Spain), S. García Gil (Santa Cruz de Tenerife, Spain), J. Dorca Sargatal (Barcelona, Spain), A. Medina Gonzálvez (Santa Cruz de Tenerife, Spain), O. Acosta Fernández (Santa Cruz de Tenerife, Spain), M. Molina Molina (Barcelona, Spain)
| |
EVALUATION OF THE PALLIATIVE CRITERIA IN IDIOPATHIC PULMONARY FIBROSIS
O. Bronte Moreno (Galdakao, Spain), M. Aburto (Galdakao, Spain), L. Chasco (Galdakao, Spain), I. Arrizubieta (Galdakao, Spain), I. Gorordo (Galdakao, Spain), L. Altube (Galdakao, Spain), J. Moraza (Galdakao, Spain), C. Esteban (Galdakao, Spain), P. España (Galdakao, Spain)
| |
Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth
M. Wijsenbeek (Rotterdam, Netherlands), E. Santermans (Mechelen, Belgium), P. Ford (Mechelen, Belgium), M. Kreuter (Heidelberg, Germany), N. Verbruggen (Mechelen, Belgium), P. Meyvisch (Mechelen, Belgium), W. Wuyts (Leuven, Belgium), K. Brown (Denver, CO, United States of America), D. Lederer (New York, NY, United States of America), T. Maher (London, United Kingdom)
| |
Incidence of MUC5B minor allele in end-stage lung disease and implications for transplantation
S. Verleden (Leuven, Belgium), L. De Saedeleer (Leuven, Belgium), A. Van Herck (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), G. Verleden (Leuven, Belgium), R. Vos (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
| |
Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?
P. Mari (Rome, Italy), S. Kay (Ann Arbor, United States of America), E. Belloli (Ann Arbor, United States of America), M. Salisbury (Ann Arbor, United States of America), J. Sheth (Ann Arbor, United States of America), C. Holtze (Ann Arbor, United States of America), B. Wang (Ann Arbor, United States of America), J. Myers (Ann Arbor, United States of America), K. Konopka (Ann Arbor, United States of America), A. Lagstein (Ann Arbor, United States of America), E. Kazerooni (Ann Arbor, United States of America), A. Chughtai (Ann Arbor, United States of America), D. Vummidi (Ann Arbor, United States of America), V. Nagaraja (Ann Arbor, United States of America), D. Khanna (Ann Arbor, United States of America), K. Flaherty (Ann Arbor, United States of America), L. Richeldi (Rome, Italy), E. White (Ann Arbor, United States of America)
| |